Ultime notizie per Evofem Biosciences (OTC:EVFM) Azioni

Evofem Biosciences

Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.

EVOFEM BIOSCIENCE INC by Evofem Biosciences, Inc.

Evofem Biosciences Inc

Earnings

Earnings Beats

News

CORRECTION: Fabrinet Q3 Adj. EPS $2.52 Beats $2.49 Estimate, Sales $871.80M Beat $856.62M Estimate

Management

Fold Holdings Appoints Matthew McManus As COO, Effective 21, 2025

Teradata Appoints John Ederer As CFO

RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) has outperformed the market over the past 5 years by 2.97% on an annualized basis producing an average annual return of 16.99%. Currently, RTX has a market capitalization of $171.67 billion. 
Buying $100 In RTX: If an investor had bought $100 of RTX stock 5 years ago, it would be worth $225.56 today based on a price of $128.50 for RTX at the time of writing.
<h3>RTX's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746477912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

CRH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRH#NYSE">CRH</a>), the leading provider of building materials solutions, is pleased to announce that it has completed the latest phase of its share buyback program, returning a further $0.3 billion of cash to shareholders.
Between February 27, 2025 and May 2, 2025, 3.3 million ordinary shares listed on the New York Stock Exchange were repurchased. This brings total cash returned to shareholders under our ongoing share buyback program to $8.8 billion since its commencement in May 2018.
CRH today also announces that it has entered into an arrangement with BNP Paribas Securities Corp. ("BNPP") to repurchase ordinary shares listed on the New York Stock Exchange on CRH's behalf for an aggregate maximum consideration of up to $0.3 billion (the "Buyback"). The Buyback will commence on May 6, 2025, and will end no later than August 5, 2025.
BNPP will conduct the Buyback on CRH's behalf and will make trading decisions under the Buyback independently of CRH in accordance with certain pre-set parameters. The maximum number of ordinary shares which may be acquired pursuant to the Buyback is 40,000,000. The purpose of the Buyback is to reduce the share capital of CRH.
The Buyback will be conducted within the parameters prescribed by (i) Rule 10b5-1 and Rule 10b-18 under the U.S. Securities Exchange Act of 1934, as amended and (ii) the EU Market Abuse Regulation (596/2014) and Commission Delegated Regulation (EU) 2016/1052 as such legislation forms part of the law in the United Kingdom ("UK") pursuant to the EU (Withdrawal) Act 2018 (as may be amended and/or supplemented from time to time). No repurchases will be made outside of the United States. The repurchased ordinary shares will be cancelled.

Buybacks

CRH Announces That It Has Completed Latest Phase Of Its Share Buyback Program Of $0.3B Of Cash To Shareholders

Builders FirstSource, Inc. (NYSE:<a href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) ("Builders FirstSource" or the "Company") today announced that it has priced an offering of $750 million aggregate principal amount of 6.750% unsecured Senior Notes due 2035 (the "Notes"), which represents a $250 million increase in the previously announced size of the offering. The price to investors will be 100.000% of the principal amount of the Notes.
The offering of the Notes is expected to close on May 8, 2025, subject to customary closing conditions. The Company intends to use the net proceeds from the offering to repay indebtedness outstanding under its senior secured ABL facility.

Offerings

BLDR

Builders FirstSource Prices Offering Of $750M Of Senior Notes Due 2035

Guidance

AROC

Archrock Sees FY25 Contract Operations Revenue $1.260M-$1.290M

Gibson Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GEI#TSX">GEI</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.25 by 20 percent. This is a 20 percent increase over earnings of $0.25 per share from the same period last year. The company reported $2.75 billion in sales this quarter. This is a 16.45 percent decrease over sales of $3.29 billion the same period last year.

TSX:GEI

Gibson Energy Q1 EPS $0.30 Beats $0.25 Estimate, Sales $2.75B Down From $3.29B YoY

Hims &amp; Hers Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) reported financial results for the first quarter on Monday after the bell. Here&#8217;s a look at the key details <a href="https://www.benzinga.com/pressreleases/25/05/b45206384/hims-hers-health-inc-reports-first-quarter-2025-financial-results">from the print</a>.
Q1 Earnings: Hims &amp; Hers Health reported first-quarter revenue of $586.01 million, beating&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $538.2 million, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The company reported first-quarter earnings of 20 cents per share, beating analyst estimates of 12 cents per share. 
Total revenue was up 111% on a year-over-year basis as subscribers grew to 2.4 million in the quarter, up 38% year-over-year. Gross margin came in at 73% in the first quarter. The company reported operating cash flow of $109.1 million and free cash flow of $50.1 million in the quarter.
&#8220;We&#8217;re starting 2025 with incredible momentum. Millions of people are turning to us for access to care that is personal, affordable, and has the potential to drive better outcomes,&#8221; said&nbsp;Andrew Dudum, co-founder and CEO of Hims &amp; Hers Health.
&#8220;We&#8217;re building a platform that puts the individual at the center of every decision and others are taking notice. Over time, we expect wider collaboration across the industry, inclusive of pharmaceutical players, innovative leaders in diagnostic and preventative testing, and world-class providers.&#8221;
Guidance: Hims &amp; Hers Health guided for second-quarter revenue of $530 million to $550 million versus estimates of $564.56 million.
The company continues to expect full-year 2025 revenue to be in the range of $2.3 billion to $2.4 billion versus estimates of $2.32 billion, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Hims &amp; Hers Health also provided a longer-term outlook, laying out expectations for at least $6.5 billion in annual revenue for full-year 2030, and adjusted EBITDA of at least $1.3 billion.
Hims &amp; Hers executives will hold a conference call at 5 p.m. ET to further discuss the company&#8217;s quarterly performance.
HIMS Price Action: <a href="http://benzinga.com/quote/hims" target="_blank" rel="noreferrer noopener">Hims &amp; Hers Health shares</a> were down 1.03% at $41.45 in Monday&#8217;s after-hours session at publication time, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/05/45196511/hims-hers-appoints-ex-amazon-exec-ahead-of-q1-results">Hims &amp; Hers Appoints Ex-Amazon Exec Ahead Of Q1 Results</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/StormyDays">Lori Butcher</a>/Shutterstock.

Health Care

After-Hours Center

Movers

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health Q1 Earnings: Revenue Jumps 111%, Subscribers Up 38%, Q2 Guidance Falls Short Of Estimates, Shares Slide

Regal Rexnord (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRX#NYSE">RRX</a>) affirms FY2025 Adj EPS guidance from $9.60-$10.40 to $9.60-$10.40 vs $9.64 analyst estimate..

Regal Rexnord Affirms FY2025 Adj EPS Guidance of $9.60-$10.40 vs $9.64 Est

TrueBlue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBI#NYSE">TBI</a>) sees Q2 sales of $392.000 million-$417.000 million vs $380.18 million analyst estimate.

TrueBlue Sees Q2 Sales $392.000M-$417.000M vs $380.18M Est

Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>), a global leader in electrical balance of system (EBOS) solutions for the energy transition market, announced today the execution of a Memorandum of Understanding (MOU) with UGT Renewables to collaborate on up to 12 gigawatts (GW) of global solar projects currently in UGT Renewables' development pipeline. This collaboration aims to bring innovative EBOS solutions to emerging markets, accelerating the energy transition and supporting sustainable development.
"We are always seeking best-in-class providers for our projects in order to deliver world-class American-led energy installations. We have a history with Shoals and are pleased to memorialize our intent to collaborate with Shoals regarding our existing 12GW of solar projects in the pipeline," Adam Cortese, CEO of UGT Renewables and Sun Africa said. "We have great confidence in Shoals' ability to design and deliver an EBOS solution that can operate efficiently in complex environments and is backed by an industry leading warranty. Shoals' BLA solution enables a superior levelized cost of electricity and requires less skilled labor than other solutions, which supports our need to accelerate reliable, low-cost electrification in emerging markets."
UGT Renewables partners with emerging markets and developing economies that are looking to diversify their energy matrix. In the Southern Provinces of Angola, Shoals and UGT Renewables' sister company, Sun Africa, have aligned to execute on the first two energy diversification projects with a combined capacity of 600 MW of Solar PV planned to begin deployment later this year.
These first projects, financed by EXIM Bank in the United States, are expected to break ground in 2025 and will play a crucial role in electrifying 60% of the Angolan population, providing clean water to over 1.1 million people.
"This collaboration with UGT Renewables and Sun Africa strengthens our position within international markets," Brandon Moss, CEO of Shoals stated. "We are looking forward to working together on these current projects and the opportunity to collaborate on future potential projects by supporting the deployment of our high-quality and innovative solutions."

Contracts

SHLS

Shoals Technologies Group, UGT Renewables And Sun Africa Announces Collaboration On Up To 12GW Of Solar Projects

Biotech

General

ARAY

Accuray Reports First SRS/SBRT Patient Treatments in Austria With the CyberKnife System

Archrock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AROC#NYSE">AROC</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.38 by 10.53 percent. This is a 61.54 percent increase over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $347.20 million which beat the analyst consensus estimate of $342.79 million by 1.29 percent. This is a 29.32 percent increase over sales of $268.49 million the same period last year.

Archrock Q1 Adj. EPS $0.42 Beats $0.38 Estimate, Sales $347.20M Beat $342.79M Estimate

Regal Rexnord (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRX#NYSE">RRX</a>) reported quarterly earnings of $2.15 per share which beat the analyst consensus estimate of $1.83 by 17.49 percent. This is a 7.5 percent increase over earnings of $2.00 per share from the same period last year. The company reported quarterly sales of $1.42 billion which beat the analyst consensus estimate of $1.37 billion by 3.63 percent. This is a 8.39 percent decrease over sales of $1.55 billion the same period last year.

Regal Rexnord Q1 Adj. EPS $2.15 Beats $1.83 Estimate, Sales $1.42B Beat $1.37B Estimate

Ford Motor Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) released its first-quarter results after Monday's closing bell. Here's a look at the key figures from the report. 
The Details: Ford Motor reported quarterly earnings of 14 cents per share, which beat the analyst consensus estimate of two cents, but is down from earnings of 49 cents per share from the prior year&#8217;s quarter. Quarterly revenue came in at $37.42 billion, which beat the analyst consensus estimate of $36.2 billion and is down from revenue of $39.89 billion from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/earnings/25/05/45194998/saudi-arabias-oil-power-play-jolts-markets-can-diamondback-and-rivals-survive-the-squeeze?utm_source=articleShare">Saudi Arabia&#8217;s Oil Power Play Jolts Markets: Can Diamondback And Rivals Survive The Squeeze?</a>
For the first quarter, Ford reported: 
<ul>
<li>Ford Pro generated $1.3 billion in EBIT with a margin of 8.6% on $15.2 billion in revenue. </li>
<li>Ford Model e reported a first-quarter EBIT loss of $849 million. </li>
<li>Ford Blue reported $96 million in EBIT, down from a year ago due to expected volume decline and adverse exchange. Segment revenue declined 3% to $21 billion.</li>
<li>Ford Credit reported first-quarter earnings before taxes (EBT) of $580 million, up significantly compared to a year ago. </li>
</ul>
&#8220;We are strengthening our underlying business with significantly better quality and our third straight quarter of year-over-year cost improvement, excluding the impact of tariffs," said Ford CEO Jim Farley. 
"Ford Pro, our largest competitive advantage, is off to a strong start to the year, gaining market share in the most profitable U.S. and European customer segment,&#8221; Farley added.
Outlook: Ford suspended its financial guidance, including full-year adjusted EBIT and adjusted free cash flow, due to tariff-related uncertainty.
F Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Ford Motor stock was down 2.46% after hours at $9.92 on Monday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/management/25/05/45180224/these-ev-makers-could-shine-if-musk-leaves-tesla?utm_source=articleShare">These EV Makers Could Shine If Musk Leaves Tesla</a></li>
</ul>
Image: Shutterstock

Ford Stock Hits The Brakes After Q1 Earnings, Suspends Guidance Due To 'Tariff-Related Uncertainty'

Elanco Animal Health Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) on Monday announced the sale of certain future tiered royalties and commercial milestones associated with Xdemvy (lotilaner ophthalmic solution) 0.25% for the human health application of lotilaner to Blackstone Life Sciences and&nbsp;Blackstone Credit&nbsp;&amp; Insurance for&nbsp;$295 million&nbsp;in cash.
The company will use the proceeds to accelerate debt reduction, positioning Elanco to achieve an expected net leverage ratio of 3.9x to 4.3x adjusted EBITDA <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45189850/elanco-sells-royalty-and-milestone-rights-for-lotilaner-in-human-health-to-blackstone-accelerates-" rel="noreferrer noopener">by the end of 2025</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43951589/elanco-animals-outlook-lags-street-expectations-but-analyst-sees-time-for-elancos-commercial-investment-to-payoff" rel="noreferrer noopener">Elanco Animal's Outlook Lags Street Expectations, But Analyst Sees Time For Elanco's Commercial Investment To Payoff</a>
Elanco will repay portions of its outstanding term loans on a pro-rata basis, which is expected to reduce interest expense by approximately&nbsp;$10 million, offset by the sale of approximately&nbsp;$10 million&nbsp;of royalties based on Elanco's initial 2025 guidance.
In 2019, Elanco exclusively licensed lotilaner to Tarsus Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) for exploration as a solution to several unmet human health needs.
In 2023, Xdemvy became the first lotilaner-based product approved for human use and the only FDA-approved medicine for Demodex&nbsp;blepharitis, a common eyelid disease in humans caused by&nbsp;Demodex&nbsp;mites.
The agreement applies to certain tiered royalties associated with Xdemvy's U.S. net sales from&nbsp;April 2025&nbsp;through&nbsp;August 2033&nbsp;and certain commercial milestones.
Elanco retains the rights to all royalty payments on net sales outside the U.S. and any future human applications of lotilaner beyond ophthalmic solutions.&nbsp;&nbsp;
Elanco Animal Health is scheduled to release its first quarter 2025 financial results on&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44731940/elanco-confirms-date-and-conference-call-for-first-quarter-2025-financial-results-announcement" rel="noreferrer noopener">Wednesday, May 7</a>.
Analysts expect adjusted earnings per share of 31 cents and sales of $1.21 billion, as per data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
<h2 class="wp-block-heading">Elanco Health Stock Prediction For 2025</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Elanco Animal Health, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Elanco Animal Health, the 200-day moving average sits at $12.34, according to <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">Benzinga Pro</a>, which is above the current price of $9.75. For more on charts and trend lines, <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: ELAN stock closer lower by 1.03% to $9.65 and TARS stock lower by 1.35% to $48.00 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/05/45179007/becton-dickinson-vitals-drop-analysts-have-been-wrong-on-this-med-tech-stock-for-years" target="_blank" rel="noreferrer noopener">Becton Dickinson Vitals Drop: Analysts ‘Have Been Wrong' On This Med Tech Stock For Years</a></li>
</ul>
Photo by T Sxhneider via Shutterstock

Large Cap

ELAN

TARS

Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal

As required by the Company Guide, the Company will submit a detailed plan by May 29, 2025, advising of actions it has taken or will take to regain compliance with the continued listing standards by the compliance deadline of October 29, 2026. If NYSE Regulation determines to accept the plan, the Company will be subject to periodic reviews, including quarterly monitoring for compliance. If the plan is not accepted, or the Company does not make progress under the plan during the plan period, NYSE may commence delisting proceedings. However, the Company is entitled to appeal a staff delisting determination in accordance with the Company Guide.

BURU

NUBURU Received NYSE Noncompliance Notice

Intrepid Potash (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPI#NYSE">IPI</a>) reported quarterly earnings of $0.39 per share which beat the analyst consensus estimate of $(0.05) by 880 percent. This is a 378.57 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $97.76 million which beat the analyst consensus estimate of $82.43 million by 18.60 percent. This is a 23.30 percent increase over sales of $79.29 million the same period last year.

Intrepid Potash Q1 Adj. EPS $0.39 Vs $(-0.14) YoY, Sales $97.76M Vs 79.2M YoY

GTBP

GT Biopharma Appoints Michael Breen As CEO For Two-Year Term

Press Releases

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Small Cap

Evofem Biosciences to Present at Emerging Growth Conference

Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

Comments

Evofem Biosciences

Notizie

Ultime notizie per Evofem Biosciences (OTC:EVFM) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO